Download Files:
Irinotecan
$72 – $312
Products Details
Product Description
– Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].
Web ID
– HY-16562
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C33H38N4O6
Citations
– Apoptosis. 2016 Feb;21(2):130-42. |Biochem Pharmacol. 2023 Aug 25;115752.|Biomaterials. 16 September 2022.|Biomed Pharmacother. 2020 Aug;128:110262.|Biomed Pharmacother. 2023 Apr 25;163:114751.|bioRxiv. 2019 Dec.|Cancer Lett. 2022 Nov 30;216028.|Cell Biosci. 2023 Nov 25;13(1):215.|Cell Death Dis. 2019 Nov 25;10(12):887. |Cell Discov. 2022 Sep 14;8(1):92.|Cell Rep Med. 2023 Jan 10;100911.|Cell. 2022 Sep 1;185(18):3356-3374.e22.|Clin Cancer Res. 2023 Sep 19.|EBioMedicine. 2023 May 9;92:104594.|Eur J Pharm Biopharm. 2022 Jan 5;S0939-6411(21)00272-1.|Eur J Pharmacol. 2023 Apr 11;949:175718.|Gastroenterology. 2021 Nov;161(5):1601-1614.e23.|Gene. 2019 Mar 10;688:1-6. |Genome Med. 2016 Oct 31;8(1):116.|Heliyon. 2023 Apr 21.|INT J PHARMACEUT. 2020 May.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Pharm Pharmacol. 2023 Mar 1;rgad007.|Life Sci. 2019 Aug 15;231:116529. |Lung Cancer. 2023 Mar 8;178:237-246.|Mol Biol Cell. 2023 Mar 29;mbcE22110518.|Mol Cancer Ther. 2021 Oct 28.|Mol Cancer Res. 2020 Mar;18(3):414-423.|Patent. US20210009719A1.|Pharmacol Res. 2021 Jan;163:105232.|PLoS Biol. 2022 Feb 24;20(2):e3001517.|PLoS Pathog. 2020 Mar 24;16(3):e1008429.|Signal Transduct Target Ther. 2021 May 28;6(1):188.|Theranostics. 2019 May 31;9(13):3732-3753.|Apoptosis. 2019 Apr;24(3-4):312-325.|Cancers (Basel). 2023 Sep 6, 15(18), 4442.|Front Immunol. 2018 Jan 5;8:1919.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Ruperto Carola University Heidelberg. Natural Sciences and Mathematics. 18 March 2022.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
References
– [1]Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26.|[2]Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30.|[3]Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.|[4]Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116.|[5]Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21(2):130-42.
CAS Number
– 97682-44-5
Molecular Weight
– 586.68
Compound Purity
– 99.84
SMILES
– O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 25 mg/mL (ultrasonic)
Target
– Autophagy;Topoisomerase
Isoform
– Topo I
Pathway
– Autophagy;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
